featured
Sacituzumab Govitecan Promising in Triple-Negative Breast Cancer
Response rate of 33.3 percent, median response duration of 7.7 months observed in 108 patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.